Lilly’s breast cancer drug, abemaciclib given in combination with fulvestrant has met its primary endpoint of progression-free survival (PFS) in a phase 3 breast cancer trial.
Indianapolis-based Lilly has reported that its breast cancer drug, abemaciclib, in combination with fulvestrant, has yielded positive results by meeting its primary endpoint, progression-free survival (PFS) in a phase 3 breast cancer trial. The combination of Lilly breast cancer drug abemaciclib with fulvestrant was proved to be more effective than the fulvestrant plus placebo combination […]
Check out results of the late-breaking blood thinner clinical trial of Rivaroxaban, Bayer & Janssen’s oral blood thinner for deep vein thrombosis treatment.
Bayer and Janssen Pharmaceuticals have revealed that their jointly developed oral blood thinner Xarelto (rivaroxaban) had considerably brought down the risk of recurring formation of life-threatening blood clots in the vein as per the findings of their late-breaking study. Rivaroxaban Blood Thinner Clinical Trial This, they demonstrated in a blood thinner clinical trial dubbed EINSTEIN CHOICE. […]
Check out details of Astrazeneca Ovarian Cancer Drug, Lynparza which in a phase 3 trial has been demonstrated to have improved survival of patients treated with Lynparza Ovarian Cancer Tablets.
Pharma giant AstraZeneca has reported that its ovarian cancer drug Lynparza (olaparib) as a maintenance therapy has considerably improved the survival chances of patients with germline BRCA-mutations (gBRCA) who had a relapse of the disease, who did not respond to platinum-based chemo. Phase 3 Trial of Astrazeneca Ovarian Cancer Drug Lynparza The observation of the […]
Check out details of Amgen Cholesterol Injection phase 3 trial results which demonstrated that Repatha cholesterol injection with statin therapy reduce heart attack, stroke chances.
Amgen cholesterol injection Repatha (evolocumab) has been demonstrated to have cut heart attack and stroke risk by 20% in a phase 3 cardiovascular outcomes study featuring 27,564 patients with heart diseases. Amgen Cholesterol Trial for Repatha Cholesterol Injection During the trial, it was proven that by maximum reduction of low-density lipoprotein cholesterol (LDL-C) levels (bad cholesterol) […]
European cell therapy company TiGenix has announced positive top-line results for its cardiac stem cell trial evaulating its heart attack stem cell therapy AlloCSC-01 in patients facing the risk of getting heart failure after a coronary attack.
TiGenix has announced that its cardiac stem cell study assessing its heart attack stem cell therapy with AlloCSC-01 was successful in patients having the risk of heart failure following a coronary attack. Tigenix Heart Attack Stem Cell Therapy with AlloCSC-01 The Belgium biopharma stated that its Phase I/II study of donor-derived expanded cardiac stem cells (AlloCSC) […]
The UCART19 lymphoblastic leukemia drug jointly developed by Servier and Pfizer has been given the FDA clearance for its clinical development for lymphoblastic leukemia treatment.
The US Food and Drug Administration (FDA) has given the green signal to Servier and Pfizer to carry out the clinical development of their UCART19 lymphoblastic leukemia drug for relapsed/refractory acute lymphoblastic leukemia treatment. In this regard, the FDA granted the pharmas with the Investigational New Drug (IND) clearance for the allogeneic, gene-edited cellular therapy […]
As per the Actelion recent news, the pharma’s Ledaga Chlormethine Gel 160 micrograms/g has been approved by the European Commission (EC) for CTCL MF treatment.
Actelion recent news : The European Commission (EC) has approved Actelion Pharmaceuticals’ marketing authorization for its Ledaga Chlormethine Gel 160 micrograms/g for cutaneous T-cell lymphoma mycosis fungoides-type treatment, shortened as CTCL MF treatment. Ledaga Chlormethine Gel Details Approval of the topical, daily once and colorless gel by the EC comes in the wake of the […]
AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals.
AstraZeneca’s MedImmune and Sanofi Pasteur have formed a research and development alliance for a new infant respiratory drug, MEDI8897 which they are planning to commercialize after getting through the clinical trials and the necessary regulatory approvals. While MedImmune is the global biotech arm of British-Swedish pharma giant, Sanofi Pasteur is the vaccines division of French […]
The US Food and Drug Administration has approved Noctiva (desmopressin acetate) developed by Serenity Pharmaceuticals for the treatment of nocturia syndrome in adults.
Serenity Pharmaceuticals’ nasal spray to treat the nocturnal polyuria syndrome in adults, Noctiva (desmopressin acetate) has secured the US FDA approval. Nocturnal polyuria syndrome or simply nocturia syndrome is a condition where a person has to wake up more than twice during the night to urinate. Noctiva is now the first treatment for nocturnal urine […]
The jointly developed eczema drug, Dupixen (dupilumab) from Sanofi and Regeneron Pharmaceuticals has succeeded in a pivotal phase 3 Atopic dermatitis clinical trial.
Atopic dermatitis clinical trial : The jointly developed eczema drug, Dupixen (dupilumab) from Sanofi and Regeneron Pharmaceuticals has met the primary endpoints of a crucial one-year long phase 3 clinical trial in adult patients with uncontrolled moderate-to-severe atopic dermatitis (AD). Atopic Dermatitis Clinical Trial of Dupixen In the phase 3 eczema drug trial named as CHRONOS, […]